Search Results

You are looking at 1 - 10 of 136 items for :

  • "Chronic myelogenous leukemia" x
Clear All
Full access

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory and Hema Sundar

Chronic myelogenous leukemia (CML) accounts for 15% of adult leukemias. The median age at disease onset is 67 years; however, SEER statistics show that CML occurs in all age groups. 1 In 2014, an estimated 5980 people will be diagnosed with CML in the

Full access

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus

NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate

Full access

Jerald P. Radich

In the absence of stem cell transplantation, treatment of blast crisis in chronic myelogenous leukemia (CML) continues to be mostly unsuccessful and is essentially the same now as it was in 1975, declared Jerald P. Radich, MD, Director of the

Full access

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Javier Pinilla-Ibarz, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory and Hema Sundar

to: Integrate into professional practice the updates to NCCN Guidelines for Chronic Myelogenous Leukemia Describe the rationale behind the decision-making process for recent updates to the NCCN Guidelines for Chronic Myelogenous Leukemia NCCN

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

37 , 40 and Nilotinib 48 in Imatinib-Resistant or -Intolerant Patients With Chronic-Phase Chronic Myelogenous Leukemia at 24-Month Follow-Up Efficacy: Among patients with CP-CML, the overall MCyR rates for dasatinib and nilotinib at the currently

Full access

Jorge Cortes and Francis Giles

chronic myelogenous leukemia with interferon-alpha and chemotherapy . Hematol Oncol Clin North Am 1998 ; 12 : 31 – 80 . 7 Kantarjian H Melo JV Tura S . Chronic myelogenous leukemia: Disease biology and current and future therapeutic

Full access

Hema Sundar and Jerald Radich

reciprocal translocation of chromosomes 9 and 22. She was given the diagnosis of chronic phase chronic myelogenous leukemia (CP-CML), with an intermediate-risk Sokal score but a low-risk Hasford and EUTOS score. She was started on imatinib in November 2008

Full access

Susan O'Brien, Ellin Berman, Hossein Borghaei, Daniel J. DeAngelo, Marcel P. Devetten, Steven Devine, Harry P. Erba, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Tariq Mughal, Javier Pinilla-Ibarz, Jerald P. Radich, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Martin S. Tallman, Moshe Talpaz and Meir Wetzler

the express written permission of the NCCN © 2009. Disclosures for the NCCN Chronic Myelogenous Leukemia Guidelines Panel At the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from

Full access

Jerald P. Radich

“No disease has been more educational about how to move from basic understanding of molecular genetics to actual clinical care than chronic myelogenous leukemia [CML],” announced Jerald P. Radich, MD, Director of the Molecular Oncology Lab at the

Full access

Michael E O'Dwyer

– 1501 . 2 Rowley JD . A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining (Letter) . Nature 1973 ; 243 : 290 – 293 . 3 Shtivelman E Lifshitz B Gale